Roche has reported early clinical data with its candidate obesity therapy CT-388, bought as part of its $3.1 billion takeover of Carmot Therapeutics that was announced las
New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss.
Novo Nordisk’s breakneck sales growth has continued in the first quarter of this year with a 24% increase that was helped by a doubling in turnover of obesity blockbuster Wegovy
When I began practicing obesity medicine nearly 20 years ago, it was difficult for my patients to attain significant long-term weight loss without metabolic and bariatric surgery.
Going against the advice of its own advisors, the European Commission has said that PTC Therapeutics’ Translarna therapy for Duchenne muscular dystrophy (DMD) should stay
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.